| Symbol | NKTX |
|---|---|
| Name | NKARTA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 6000 SHORELINE COURT,SUITE 102, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 415 582-4923 |
| Fax | — |
| — | |
| Website | https://www.nkartatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001787400 |
| Description | Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The companys operations are based in South San Francisco, California and it operates in one segment. Additional info from NASDAQ: |
Behbahani Ali 🟢 acquired 37.0K shares (1 derivative) of Nkarta, Inc. (NKTX) at $2.46 Transaction Date: Jun 10, 2026 | Filing ID: 267632
Read moreGeorge Simeon 🟢 acquired 37.0K shares (1 derivative) of Nkarta, Inc. (NKTX) at $2.46 Transaction Date: Jun 10, 2026 | Filing ID: 267601
Read moreVratsanos George 🟢 acquired 37.0K shares (1 derivative) of Nkarta, Inc. (NKTX) at $2.46 Transaction Date: Jun 10, 2026 | Filing ID: 267538
Read moreScheiner Zachary 🟢 acquired 37.0K shares (1 derivative) of Nkarta, Inc. (NKTX) at $2.46 Transaction Date: Jun 10, 2026 | Filing ID: 267524
Read morePATTERSON LEONE D 🟢 acquired 37.0K shares (1 derivative) of Nkarta, Inc. (NKTX) at $2.46 Transaction Date: Jun 10, 2026 | Filing ID: 267521
Read moreDybbs Michael 🟢 acquired 37.0K shares (1 derivative) of Nkarta, Inc. (NKTX) at $2.46 Transaction Date: Jun 10, 2026 | Filing ID: 267519
Read moreThedinga Angela 🟢 acquired 37.0K shares (1 derivative) of Nkarta, Inc. (NKTX) at $2.46 Transaction Date: Jun 10, 2026 | Filing ID: 267517
Read moreNew Form SCHEDULE 13D/A - Nkarta, Inc. <b>Filed:</b> 2026-05-19 <b>AccNo:</b> 0001072613-26-000486 <b>Size:</b> 72 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06733935 | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) | Phase1 | Systemic Sclerosis | Recruiting | 2024-11-04 | 2028-10-01 | ClinicalTrials.gov |
| NCT06557265 | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Phase1 | Lupus Nephritis | Recruiting | 2024-06-13 | 2027-04-01 | ClinicalTrials.gov |
| NCT05020678 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (… | Phase1 | Lymphoma, Non-Hodgkin | Active_Not_Recruiting | 2021-08-20 | 2038-12-01 | ClinicalTrials.gov |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | Phase1 | Relapsed/Refractory AML | Active_Not_Recruiting | 2020-09-21 | 2039-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX101 - CAR NK cell therapy | Drug | Phase PHASE1 | Relapsed/Refractory AML | ACTIVE_NOT_RECRUITING | NCT04623944 |
| Fludarabine, Cyclophosphamide | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | Other | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| Cyclophosphamide | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX019 | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | ACTIVE_NOT_RECRUITING | NCT05020678 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine | DRUG | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| Fludarabine, Cyclophosphamide | DRUG | Phase PHASE1 | Lupus Nephritis | RECRUITING | NCT06557265 |
| NKX019 | DRUG | Phase PHASE1 | Systemic Sclerosis | RECRUITING | NCT06733935 |
| NKX101 - CAR NK cell therapy | BIOLOGICAL | Phase PHASE1 | Relapsed/Refractory AML | ACTIVE_NOT_RECRUITING | NCT04623944 |